EXTON, Pa., July 12 /PRNewswire-FirstCall/ -- ViroPharma Incorporated will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on Thursday, July 13th to discuss the recent scientific supplement to their pending petition for Stay of Action with the FDA regarding the bioequivalence requirements for abbreviated new drug applications (ANDAs) that seek to copy Vancocin capsules.
The live webcast of the conference call will be accessible via ViroPharma’s corporate website at http://www.viropharma.com. An audio archive will be available at the same address until July 28, 2006. To participate in the conference call, please dial (800) 391-2548 (domestic) and (302) 709-8328 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company’s website at http://www.viropharma.com.
ViroPharma Incorporated
CONTACT: Will Roberts, Director, Corporate Communications,+1-610-321-6288; or Robert Doody, Manager, Corporate Communications,+1-610-321-6290, both of ViroPharma
Web site: http://www.viropharma.com//
